Want to see CH:BION full AI Analyst Report?
BION Stock Chart & Stats
CHF46.80
CHF0.10(0.27%)
At close: 4:00 PM EST
CHF46.80
CHF0.10(0.27%)
Day’s Range― - ―
52-Week RangeCHF30.75 - CHF52.00
Previous CloseN/A
Volume20.47K
Average Volume (3M)98.23K
Market Cap
CHF2.81B
Enterprise ValueCHF2.07B
Total Cash (Recent Filing)CHF356.18M
Total Debt (Recent Filing)CHF0.00
Price to Earnings (P/E)3.5
Beta0.96
Next Earnings
Jul 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.95%
Share Statistics
EPS (TTM)14.49
Shares Outstanding55,149,250
10 Day Avg. Volume119,513
30 Day Avg. Volume98,228
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.89
Price to Sales (P/S)32.10
P/FCF Ratio7.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF73.00Price Target Upside55.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)2.58
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthZero reported debt in 2025 and TTM gives BB Biotech durable financial flexibility, lowering refinancing risk and enabling opportunistic capital deployment into biotech equities or return-of-capital actions. This reduces solvency risk during sector drawdowns and supports long-term portfolio management.
Improving Cash GenerationRecent positive operating and free cash flow trends provide a sustainable source to fund dividends, buybacks, or selective portfolio transactions without forced asset sales. Improving cash generation enhances resilience across the biotech cycle and supports strategic allocation over months.
Focused Investment Model & Low OverheadA concentrated biotech-focused investment mandate combined with a small operating base (low employee count) creates a low-cost structure and concentrated expertise. This supports active, high-conviction positioning able to capture outsized long-term gains from successful portfolio companies.
Bears Say
Earnings And Revenue VolatilityReported earnings are driven by valuation and one-off portfolio gains, causing revenue and margins to swing materially. This undermines predictability of recurring income and complicates forecasting for dividends or NAV stability, elevating medium-term performance uncertainty.
Dependence On External Biotech OutcomesBB Biotech's returns are structurally tied to clinical trial results, regulatory approvals, and sector sentiment—factors outside management control. Such dependencies mean fundamental company strength can be overwhelmed by idiosyncratic clinical or regulatory shocks across the portfolio.
Concentration RiskA concentrated portfolio increases exposure to single-company outcomes, amplifying NAV and earnings volatility. While conviction can drive outperformance, it also raises idiosyncratic risk and requires consistently skilled position selection to avoid persistent negative swings in shareholder returns.
BB Biotech News
BION FAQ
What was BB Biotech AG’s price range in the past 12 months?
BB Biotech AG lowest stock price was CHF30.75 and its highest was CHF52.00 in the past 12 months.
What is BB Biotech AG’s market cap?
BB Biotech AG’s market cap is CHF2.81B.
When is BB Biotech AG’s upcoming earnings report date?
BB Biotech AG’s upcoming earnings report date is Jul 24, 2026 which is in 13 days.
How were BB Biotech AG’s earnings last quarter?
BB Biotech AG released its earnings results on Apr 24, 2026. The company reported -CHF0.388 earnings per share for the quarter, missing the consensus estimate of N/A by -CHF0.388.
Is BB Biotech AG overvalued?
According to Wall Street analysts BB Biotech AG’s price is currently Undervalued.
Does BB Biotech AG pay dividends?
BB Biotech AG pays a Annually dividend of CHF2.25 which represents an annual dividend yield of 3.95%. See more information on BB Biotech AG dividends here
What is BB Biotech AG’s EPS estimate?
BB Biotech AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BB Biotech AG have?
BB Biotech AG has 55,149,250 shares outstanding.
What happened to BB Biotech AG’s price movement after its last earnings report?
BB Biotech AG reported an EPS of -CHF0.388 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.495%.
Which hedge fund is a major shareholder of BB Biotech AG?
Currently, no hedge funds are holding shares in CH:BION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BB Biotech AG
BB Biotech AG is an investment fund overseen by Bellevue Asset Management AG. This fund allocates capital to publicly traded companies worldwide, with a primary focus on firms pioneering modern biotechnology, specifically in the development of medications and diagnostic tools. The construction of its investment portfolio is guided by a fundamental analysis approach. Established on November 9, 1993, BB Biotech AG is headquartered in Switzerland.
BION Stock 12 Month Forecast
Average Price Target
CHF73.00
▲(55.98% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Options Prices
Currently, No data available
---